Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000225720 encodes a pseudogene belonging to the apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 (APOBEC3) family[5]. Pseudogenes are typically non-functional sequences resembling protein-coding genes but lacking the ability to encode functional proteins, usually due to mutations, truncations, or absence of regulatory elements[2][4][6]. Processed (retrotransposed) pseudogenes like this one are created when mRNA from a functional gene is reverse-transcribed and inserted back into the genome[2][4][6]. While most pseudogenes do not produce active RNA or protein products, a minority can play regulatory roles in gene expression (via microRNA decoys, for example), but no such function has been described for ENSG00000225720[6]. This locus is not considered a therapeutic target, does not encode a protein, and has no known role in signaling, transport, or disease as a direct drug target[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 family pseudogene.